Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letrozole in Advanced or Recurrent Endometrial Cancer
NCT00004251Phase 2Completed
- Sponsor
- Canadian Cancer Trials Group
- Start
- Jan 2000
- Primary completion
- Sep 2002
- Modality
- Orthosteric Ligands
01
Overview
Phase 2, open-label, single-arm trial of letrozole in endometrial cancer (EC), sponsored by Canadian Cancer Trials Group. Primary endpoint: Objective Tumor Response at 3 years. Started Jan 2000; status: completed.
02
Drugs
letrozole
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT00004251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004251.